Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Oraxol |
Synonyms | |
Therapy Description |
Oraxol consists of paclitaxel and HM30181A, a multidrug resistance efflux pump P-glycoprotein (P-gp) inhibitor, which may increase the bioavailability of paclitaxel (PMID: 26112004). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Oraxol | Oraxol consists of paclitaxel and HM30181A, a multidrug resistance efflux pump P-glycoprotein (P-gp) inhibitor, which may increase the bioavailability of paclitaxel (PMID: 26112004). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02730481 | Phase I | Oraxol | A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies | Completed | USA | 0 |
NCT03544567 | Phase I | Oraxol | A Pilot Study of Oraxol in Subjects With Cutaneous Angiosarcoma | Completed | USA | GBR | 2 |